ENSC · Ensysce Biosciences, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $4.71M | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M | $3.93M | — | — | — | |
| $11.84M | $10.38M | $7.22M | $7.59M | $19.84M | $4.69M | $4.39M | — | — | — | |
| $4.71M | $4.93M | $4.72M | $5.36M | $6.91M | $18.71M | — | — | — | — | |
| $20.49M | — | — | — | — | $18.71M | $1.15M | — | — | — | |
| $16.54M | $15.31M | $11.94M | $12.95M | $26.75M | $23.4M | $5.54M | $3.33M | $1.56M | — | |
| -$11.84M | -$10.24M | -$6.73M | -$10.72M | -$24.22M | -$19.87M | -$1.61M | -$3.33M | -$959.24K | -$146.7K | |
| — | -202.12% | -129.18% | -480.52% | -959.91% | -562.71% | -41.04% | — | — | — | |
| $18.83K | $18.77K | $1.29M | $353.95K | $109.53K | $1.3M | $995.5K | — | — | — | |
| $79.92K | — | — | — | — | — | $719.65K | $4.25M | $3.63M | $157.39K | |
| $48.64K | $64.76K | -$1.26M | $91.91K | $14.41K | -$9.28M | $1.45M | — | — | — | |
| $915.03K | — | — | — | — | — | $4.56M | -$512.1K | $2.68M | -$27.56K | |
| $108.59K | — | — | — | — | — | $244.49K | $555.2K | $553.92K | $3635 | |
| -$11.79M | -$10.18M | -$7.99M | -$10.63M | -$24.21M | -$29.15M | $4.31M | -$1.07M | $2.12M | -$31.19K | |
| — | -200.85% | -153.3% | -476.4% | -959.33% | -825.38% | 109.66% | — | — | — | |
| — | -$487 | -$74 | -$13.2K | -$35.39K | -$62.19K | -$217.65K | — | — | — | |
| -$11.79M | -$10.18M | -$7.99M | -$10.63M | -$25.09M | -$29.89M | $56.77K | -$2.87M | -$1.34M | -$82.61K | |
| USD/shares | — | -$3.98 | -$11.45 | -$70.40 | -$2,091.30 | -$5,335.20 | $0.00 | — | — | — |
| USD/shares | — | -$3.98 | -$11.45 | -$70.40 | -$2,091.30 | -$5,328.00 | $0.00 | — | — | — |
| shares | — | 2.56M | 697.69K | 150.94K | 12K | 5601.2611 | 4380.2014 | 1839.2481 | 1832.5058 | 1717.9183 |
| shares | — | 2.56M | 697.69K | 150.94K | 12K | 5601.2508 | 4585.3853 | 1839.2481 | 1832.5058 | 1717.9183 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2020: $196.36M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 144 similar-size Biotechnology companies (of 521 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| MPAR | $5,066,650 | $3,086,464 | $1,293,238 | $2,006,885 | $2,646,579 |
| TAAPOUD | — | $2,123,567 | $937,282 | $516,498 | $884,620 |